Skip to main content

Solid Malignancies

7
Pipeline Programs
9
Companies
9
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
267%
Small Molecule
133%
+ 8 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Immunome
ImmunomePA - Exton
2 programs
2
177Lu-IM-3050Phase 11 trial
IM-1021Phase 11 trial
Active Trials
NCT07505771Recruiting105Est. Dec 2034
NCT06823167Recruiting117Est. Feb 2029
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
2
AZD1480Phase 11 trial
[14C]AZD2014Phase 11 trial
Active Trials
NCT01112397Terminated72Est. Sep 2012
NCT02640755Completed4Est. Jul 2017
Arch Therapeutics
Arch TherapeuticsMA - Framingham
1 program
1
AR-67Phase 11 trial
Active Trials
NCT00389480Completed26Est. May 2009
Pfizer
PfizerNEW YORK, NY
1 program
1
axitinibPhase 1Small Molecule1 trial
Active Trials
NCT01540526Completed24Est. Dec 2014
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
zamzetoclaxPhase 11 trial
Active Trials
NCT05006794Active Not Recruiting145Est. Mar 2029
Labcorp
LabcorpBURLINGTON, NC
1 program
Tisotumab VedotinPHASE_1ADC
Zai Lab
Zai LabCA - South SF
1 program
Tisotumab VedotinPHASE_1ADC1 trial
Active Trials
NCT05866354Completed19Est. Nov 2023
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
zamzetoclaxPHASE_1
Carrick Therapeutics
Carrick TherapeuticsIreland - Dublin
1 program
CT7439 CapsulesPHASE_1_21 trial
Active Trials
NCT06600789Recruiting50Est. May 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Carrick TherapeuticsCT7439 Capsules
Immunome177Lu-IM-3050
ImmunomeIM-1021
Zai LabTisotumab Vedotin
Kite Pharmazamzetoclax
AstraZeneca[14C]AZD2014
Pfizeraxitinib
AstraZenecaAZD1480
Arch TherapeuticsAR-67

Clinical Trials (9)

Total enrollment: 562 patients across 9 trials

NCT06600789Carrick TherapeuticsCT7439 Capsules

A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

Start: Aug 2024Est. completion: May 202650 patients
Phase 1/2Recruiting
NCT07505771Immunome177Lu-IM-3050

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Start: Apr 2026Est. completion: Dec 2034105 patients
Phase 1Recruiting
NCT06823167ImmunomeIM-1021

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Start: Feb 2025Est. completion: Feb 2029117 patients
Phase 1Recruiting
NCT05866354Zai LabTisotumab Vedotin

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Start: Jun 2023Est. completion: Nov 202319 patients
Phase 1Completed
NCT05006794Kite Pharmazamzetoclax

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Start: Sep 2021Est. completion: Mar 2029145 patients
Phase 1Active Not Recruiting
NCT02640755AstraZeneca[14C]AZD2014

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

Start: Jan 2016Est. completion: Jul 20174 patients
Phase 1Completed
NCT01540526Pfizeraxitinib

Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib

Start: Mar 2012Est. completion: Dec 201424 patients
Phase 1Completed
NCT01112397AstraZenecaAZD1480

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

Start: Apr 2010Est. completion: Sep 201272 patients
Phase 1Terminated
NCT00389480Arch TherapeuticsAR-67

Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies

Start: Oct 2006Est. completion: May 200926 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 562 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.